RPL36A activates ERK pathway and promotes colorectal cancer growth

Jing Shi; Yebin Yang; Fangci Chen; Linpo Zhou; Haoran Wei; Fanhe Dong; Xiang Wang; Yuqiang Shan; Tianwei Chen

Translational Oncology (Jan 2025)

RPL36A activates ERK pathway and promotes colorectal cancer growth

Jing Shi,
Yebin Yang,
Fangci Chen,
Linpo Zhou,
Haoran Wei,
Fanhe Dong,
Xiang Wang,
Yuqiang Shan,
Tianwei Chen

Affiliations

Jing Shi: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People ' s Hospital, China; Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China
Yebin Yang: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People ' s Hospital, China; Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China
Fangci Chen: Department of Anorectal Surgery, First People's Hospital of LinPing District, Hangzhou, Hangzhou, Zhejiang, China
Linpo Zhou: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People ' s Hospital, China; Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China
Haoran Wei: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People ' s Hospital, China; Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China
Fanhe Dong: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People ' s Hospital, China; Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China
Xiang Wang: Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China
Yuqiang Shan: Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China; Co-Corresponding author.
Tianwei Chen: Department of Gastrointestinal Surgery, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, China; Corresponding author at: Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People ' s Hospital, School of Medicine, Westlake University, Hanghzou, China.

Journal volume & issue: Vol. 51
p. 102170

Abstract

Read online

Ribosomal protein L36A (RPL36A) was one of the most upregulated proteins in colorectal cancer (CRC), yet its role in colorectal cancer (CRC) remains largely unexplored, with limited studies investigating its expression and biological functions. In this investigation, we confirmed a marked upregulation of RPL36A in CRC tissues, correlating with an adverse prognosis. Silencing RPL36A markedly attenuated CRC cell malignant properties and tumor xenograft growth. Further mechanistic analysis indicated that RPL36A depletion diminished phosphorylated ERK levels, subsequently impacting the expression of c-Myc and ELK1, key downstream effectors in the MAPK/ERK pathway. Notably, the tumor-suppressive effects of RPL36A knockdown could be negated by an ERK activator. Collectively, our findings underscore the oncogenic function of RPL36A in CRC and propose it as a potential target for therapeutic intervention.

Published in Translational Oncology

ISSN: 1944-7124 (Print); 1936-5233 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/translational-oncology/

About the journal

Abstract

Keywords